Evidence map›Paper›PMID 27106211›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2016

Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.

Young Mi Seok, Hae Ahm Lee, Kwon Moo Park, Mi-Hyang Hwangbo, In Kyeom Kim

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Research progress on lysine acetylation (Review).International journal of molecular medicine · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Young Mi SeokCardiovascular Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, South Korea.
Hae Ahm LeeCardiovascular Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, South Korea.
Kwon Moo ParkCardiovascular Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, South Korea.
Mi-Hyang HwangboDepartment of Food Nutrition and Cookery, Keimyung College University, Daegu, Republic of Korea.
In Kyeom KimCardiovascular Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, South Korea. inkim@knu.ac.kr.
Kyungpook National University · KRKeimyung College University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of lysine deacetylase (KDAC) attenuated development of hypertension in spontaneously hypertensive rats (SHRs). We hypothesized that KDAC inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptors (MR) instead of histone acetylation in SHRs. Valproate (VPA, 0.71 % wt/vol), an inhibitor of class I KDACs, was administered in drinking water to 7-week-old SHRs and Wistar Kyoto rats for 11 weeks. MR acetylation was determined by immunoprecipitation with anti-MR antibody followed by western blot with anti-acetyl-lysine antibody. Expression levels of acetylated histone H3, KDACs, MR target genes, or MR corepressors in the kidney cortex were measured by using western blot analysis or real-time PCR. Recruitment of MR and RNA polymerase II (Pol II) and histone modifications on promoters of target genes were analyzed by performing a chromatin immunoprecipitation (ChIP) assay. Treatment of SHR with VPA increased MR acetylation without affecting MR expression, which attenuated development of hypertension in SHR VPA decreased expression of KDAC class I but globally increased acetylated histone H3. Although VPA treatment increased histone 3 acetylation (H3Ac) and trimethylation of the fourth lysine (H3K4me3) in the promoter regions of MR target genes, it decreased the expression of target genes as well as recruitment of MR and Pol II. These results suggest that KDAC inhibition attenuates the development of hypertension in SHRs and is accompanied by acetylation of MR that is independent of histone acetylation.

Indexed as

AcetylationAge FactorsAnimalsAntihypertensive AgentsBlood PressureDisease Models, AnimalGene Expression ProfilingGene Expression RegulationHistone Deacetylase InhibitorsHistone DeacetylasesHistonesHypertensionImmediate-Early ProteinsMethylationOligonucleotide Array Sequence AnalysisPromoter Regions, GeneticAntihypertensive AgentsHistone Deacetylase InhibitorsHistone DeacetylasesHistonesImmediate-Early ProteinsProtein Serine-Threonine KinasesReceptors, MineralocorticoidRNA Polymerase IISerum-Glucocorticoid Regulated KinasesTranscription FactorsTsc22d3 protein, ratValproic AcidAcetylationHypertensionInhibition of lysine deacetylaseMineralocorticoid receptorSpontaneously hypertensive rats

Identifiers

PMID27106211
OpenAlexW2342255486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.